Compare SHAZ & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHAZ | MYGN |
|---|---|---|
| Founded | 2024 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 386.9M | 444.2M |
| IPO Year | N/A | 1996 |
| Metric | SHAZ | MYGN |
|---|---|---|
| Price | $62.47 | $4.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $46.67 | $7.64 |
| AVG Volume (30 Days) | 632.9K | ★ 1.5M |
| Earning Date | 06-23-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | $8,711.27 | $6.86 |
| Revenue Next Year | $587.87 | $5.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $16.55 | $3.53 |
| 52 Week High | $86.94 | $8.59 |
| Indicator | SHAZ | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.16 | 57.08 |
| Support Level | $47.51 | $4.55 |
| Resistance Level | $86.94 | $5.42 |
| Average True Range (ATR) | 8.71 | 0.28 |
| MACD | -2.00 | 0.09 |
| Stochastic Oscillator | 33.00 | 81.74 |
SharonAI Holdings Inc is a high-performance computing (HPC) company deploying large-scale energy and compute infrastructure, USA energy markets and infrastructure asset management. Its services include: Sovereign AI Australia, GPU-as-a-Service, SHARON AI Cloud, SHARON AI Private Cloud, Virtual Private Clusters, HPC Servers, SHARON AI Supercluster, GPU Fleet, Virtual Servers, Cloud Storage, AI Model Training, High-Performance Computing (HPC), and Video Encoding & Decoding. The company's products are: Sovereign AI Australia, GPU-as-a-Service, SHARON AI Cloud, SHARON AI Private Cloud, Virtual Private Clusters, HPC Servers, SHARON AI Supercluster, GPU Fleet, Virtual Servers, Cloud Storage, AI Model Training, High Performance Computing (HPC), and Video Encoding & Decoding.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.